News

TFDA Approves CEMMA and LipoCoat Coated Antifouling CVC Catheter

Regulatory Approval Milestone in Taiwan

Jasper van Weerd
May 28, 2025

Introduction

TFDA approves CEMMA and LipoCoat co-developed coated antifouling central venous catheter. TFDA Approval Press ReleaseTaipei / Enschede, May 28, 2025 — CEMMA Medical and LipoCoat announce medical device approval by the Taiwan Food and Drug Administration (TFDA) for their antifouling CVC catheter featuring LipoCoat's non-antibiotic lipid coating.
TFDA Approval Press ReleaseTaipei / Enschede, May 28, 2025 — CEMMA Medical and LipoCoat announce medical device approval by the Taiwan Food and Drug Administration (TFDA) for their antifouling CVC catheter featuring LipoCoat's non-antibiotic lipid coating.
TFDA Approval Registration Details

Explore Partnership Opportunities

Connect with our business development team to discuss OEM partnerships and regulatory strategy.

Updates

Also interesting

LipoCoat and SonoCoat have earned recognition from leading institutions and regulatory bodies. Our coatings meet the highest standards for biocompatibility and clinical efficacy.

Document

A coating inspired from the cell membrane: LipoCoat® in three applications

LipoCoat® is a 5 nm phospholipid coating that stops proteins and bacteria from adhering. What the new technology brochure shows for catheters, contact lenses and needles, and how it fits your production line.

News

Lipocoat celebrates its 10th anniversary and breaks ground on a new production lab in Enschede.

LipoCoat is building a 500-square-meter production lab across from the University of Twente and is marking its tenth anniversary. Constantijn van Oranje started construction.

Publication

SonoCoat® Technology Featured in Scientific Publications

Four independent peer-reviewed studies have evaluated SonoCoat®, from EUS-FNA needles to prostate brachytherapy. What each one tested, and what it found.